Copeland Capital Management’s AbbVie ABBV Stock Holding History

Copeland Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,248	Closed	-$271K	–	266
2026 Q1	$271K	Sell	1,248 -60	-5%	-$13.3K	0.01%	150
2025 Q4	$299K	Hold	1,308	–	–	0.01%	145
2025 Q3	$303K	Hold	1,308	–	–	0.01%	144
2025 Q2	$243K	Hold	1,308	–	–	0.01%	141
2025 Q1	$274K	Hold	1,308	–	–	0.01%	139
2024 Q4	$232K	Sell	1,308 -15	-1%	-$2.76K	﹤0.01%	142
2024 Q3	$261K	Hold	1,323	–	–	﹤0.01%	142
2024 Q2	$227K	Hold	1,323	–	–	﹤0.01%	144
2024 Q1	$241K	Sell	1,323 -116	-8%	-$20K	﹤0.01%	139
2023 Q4	$223K	Sell	1,439 -206	-13%	-$30K	﹤0.01%	129
2023 Q3	$245K	Sell	1,645 -10	-0.6%	-$1.47K	0.01%	135
2023 Q2	$223K	Sell	1,655 -15	-0.9%	-$2.2K	﹤0.01%	136
2023 Q1	$266K	Sell	1,670 -50	-3%	-$7.64K	0.01%	135
2022 Q4	$278K	Hold	1,720	–	–	0.01%	136
2022 Q3	$231K	Sell	1,720 -145	-8%	-$20.8K	0.01%	137
2022 Q2	$286K	Sell	1,865 -10	-0.5%	-$1.53K	0.01%	133
2022 Q1	$304K	Sell	1,875 -78	-4%	-$11.3K	0.01%	131
2021 Q4	$264K	Hold	1,953	–	–	0.01%	135
2021 Q3	$211K	Sell	1,953 -25	-1%	-$2.86K	0.01%	140
2021 Q2	$223K	Hold	1,978	–	–	0.01%	137
2021 Q1	$214K	Hold	1,978	–	–	0.01%	139
2020 Q4	$212K	Hold	1,978	–	–	0.01%	135
2020 Q3	$173K	Hold	1,978	–	–	0.01%	130
2020 Q2	$194K	Hold	1,978	–	–	0.01%	124
2020 Q1	$151K	Sell	1,978 -74	-4%	-$6.3K	0.01%	131
2019 Q4	$182K	Hold	2,052	–	–	0.01%	139
2019 Q3	$155K	Sell	2,052 -331	-14%	-$22.7K	0.01%	137
2019 Q2	$173K	Sell	2,383 -350	-13%	-$27.5K	0.01%	136
2019 Q1	$220K	Sell	2,733 -1,000	-27%	-$81.8K	0.01%	129
2018 Q4	$344K	Sell	3,733 -140	-4%	-$12.3K	0.02%	124
2018 Q3	$366K	Sell	3,873 -485	-11%	-$46K	0.02%	134
2018 Q2	$404K	Buy	4,358 +160	+4%	+$15.6K	0.02%	129
2018 Q1	$397K	Sell	4,198 -501	-11%	-$55K	0.03%	125
2017 Q4	$454K	Buy	4,699 +16	+0.3%	+$1.51K	0.03%	133
2017 Q3	$416K	Hold	4,683	–	–	0.03%	128
2017 Q2	$340K	Sell	4,683 -108	-2%	-$7.26K	0.02%	122
2017 Q1	$303K	Sell	4,791 -465	-9%	-$29.2K	0.02%	126
2016 Q4	$329K	Hold	5,256	–	–	0.02%	133
2016 Q3	$331K	Sell	5,256 -150	-3%	-$9.71K	0.02%	161
2016 Q2	$335K	Sell	5,406 -230	-4%	-$14K	0.02%	148
2016 Q1	$322K	Hold	5,636	–	–	0.02%	143
2015 Q4	$334K	Hold	5,636	–	–	0.02%	160
2015 Q3	$307K	Sell	5,636 -120	-2%	-$7.81K	0.02%	149
2015 Q2	$387K	Sell	5,756 -70	-1%	-$4.57K	0.02%	175
2015 Q1	$341K	Hold	5,826	–	–	0.02%	180
2014 Q4	$381K	Sell	5,826 -875	-13%	-$55.2K	0.03%	150
2014 Q3	$387K	Sell	6,701 -200	-3%	-$11.1K	0.04%	130
2014 Q2	$389K	Buy	6,901 +365	+6%	+$19.1K	0.04%	124
2014 Q1	$336K	Sell	6,536 -8,000	-55%	-$404K	0.04%	124
2013 Q4	$768K	Hold	14,536	–	–	0.1%	77
2013 Q3	$650K	Buy	14,536 +1,000	+7%	+$44.3K	0.1%	76
2013 Q2	$560K	Buy	+13,536	New	+$592K	0.1%	71

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Copeland Capital Management's ABBV Position: Q2 2026 in Review

Copeland Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 1,248 shares — an estimated $271K sold.

Copeland Capital Management first reported a position in ABBV in Q2 2013 and held it in 52 quarters. The position peaked at $768K in Q4 2013. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Copeland Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Copeland Capital Management sold 1,248 AbbVie shares in Q2 2026, an estimated $271K.
Copeland Capital Management first reported a position in AbbVie in Q2 2013 and held it in 52 quarters.
Copeland Capital Management's AbbVie position peaked at $768K in Q4 2013.
4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Copeland Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.